td139
Small moleculeexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02257177)
Timeline
Indications
Mechanism of action
- Galectin-3INHIBITOR
LGALS3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- td139
- td139
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04473053 | Phase 2/Phase 3 (Phase 3) | Jul 3, 2020 | Latus Therapeutics, University of Edinburgh, University of Oxford |
| NCT03832946 | Phase 2 | Feb 19, 2019 | Galecto Biotech, Imperial College London, Syneos Health |
| NCT02257177 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2014 | Galecto Biotech, University of London |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galecto Biotech | For profit | 2 | 2 | 1 | 2014 |
| Imperial College London | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Latus Therapeutics | For profit | 1 | 0 | 1 | 2020 |
| Syneos Health | For profit | 1 | 0 | 1 | 2019 |
| University of Edinburgh | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1